Key result
Levosimendan increases contractility without raising mortality in acute and advanced HF, retaining efficacy alongside beta-blockers.
Why the study?
Acute and advanced heart failure carry poor short- and longer-term prognoses requiring complex therapies to restore haemodynamic balance and perfusion, prompting a summary of the role of levosimendan.
Does levosimendan provide safe and effective haemodynamic support in patients with acute and advanced heart failure?
Does levosimendan provide safe and effective haemodynamic support in patients with acute and advanced heart failure?
Levosimendan offers a favorable haemodynamic and safety profile for patients with acute and advanced heart failure, particularly those on beta-blockers, supporting its intermittent use.
Answers are grounded in this paper and cite their sources.
Supports levosimendan consideration in beta-blocked acute HF; leaves open confirmatory RCTs on renal and mortality effects.
Acute and advanced heart failure are associated with substantial adverse short- and longer-term prognosis. Both conditions necessitate complex treatment choices to restore haemodynamic stability and organ perfusion, relieve congestion, improve symptoms and allow the patient to leave the hospital and achieve an adequate quality of life. Among the available intravenous vasoactive therapies, inotropes constitute an option when an increase in cardiac contractility is needed to reverse a low output state. Within the inotrope category, levosimendan is well suited to the needs of both sets of patients since, in contrast to conventional adrenergic inotropes, it has not been linked in clinical trials or wider clinical usage with increased mortality risk and retains its efficacy in the presence of beta-adrenergic receptor blockade; it is further believed to possess beneficial renal effects. The overall haemodynamic profile and clinical tolerability of levosimendan, combined with its extended duration of action, have encouraged its intermittent use in patients with advanced heart failure. This paper summarises the key messages derived from a series of 12 tutorials held at the Heart Failure 2019 congress organised in Athens, Greece, by the Heart Failure Association of the European Society of Cardiology.
No takes yet. Share an insight, caveat, or question.
Agostoni et al. (2019) conducted a review in Acute and advanced heart failure. Levosimendan vs. Conventional adrenergic inotropes was evaluated. Levosimendan is well suited for acute and advanced heart failure as it increases cardiac contractility without increasing mortality risk and retains efficacy in the presence of beta-blockers.
Synapse has enriched 10 related papers. Consider them for comparative context: